Ulinastatin protects against lipopolysaccharide-inducedcardiac microvascular endothelial cell dysfunction viadownregulation of lncRNA MALAT1 and EZH2 in sepsis

International Journal of Molecular Medicine

Volumn 39, Issue 5, 2017, Pages 1269-1276

  Yu, Zhaoxia ^a   Rayile, Aisa ^a   Zhang, Xiangyang ^a   Li, Ying ^a   Zhao, Qiang ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Long non coding RNA metastasis associated lung adenocarcinoma transcript 1; Sepsis, cardiac microvascular endothelial cells dysfunction; Ulinastatin

Indexed keywords

CASPASE 3; DICHLOROFLUORESCEIN; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; LIPOPOLYSACCHARIDE; LONG UNTRANSLATED RNA; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; ULINASTATIN; UNCLASSIFIED DRUG; GLYCOPROTEIN; MALAT1 LONG NONCODING RNA, RAT; PROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CARDIAC MICROVASCULAR ENDOTHELIAL CELL; CARDIAC MUSCLE CELL; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CELL ISOLATION; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CELL STIMULATION; CELLULAR PARAMETERS; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; IMMUNOPRECIPITATION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RAT; RAT MODEL; REAL TIME POLYMERASE CHAIN REACTION; RNA IMMUNOPRECIPITATION; SEPSIS; TRANSENDOTHELIAL ELECTRICAL RESISTANCE; UPREGULATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; METABOLISM; PERMEABILITY;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION; GLYCOPROTEINS; MALE; PERMEABILITY; PROTECTIVE AGENTS; RATS; REACTIVE OXYGEN SPECIES; RNA, LONG NONCODING; SEPSIS;

EID: 85018738271     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2017.2920     Document Type: Article

References (43)

1. Sprung CL and Reinhart K: Definitions for sepsis and septic shock. JAMA 316: 456-457, 2016.
2. Brun-Buisson C, Meshaka P, Pinton P and Vallet B; EPISEPSIS Study Group: EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 30: 580-588, 2004.
3. Gaieski DF, Edwards JM, Kallan MJ and Carr BG: Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41: 1167-1174, 2013.
4. Zaky A, Deem S, Bendjelid K and Treggiari MM: Characterization of cardiac dysfunction in sepsis: An ongoing challenge. Shock 41: 12-24, 2014.
5. Lush CW and Kvietys PR: Microvascular dysfunction in sepsis. Microcirculation 7: 83-101, 2000.
6. Scarabelli T, Stephanou A, Rayment N, Pasini E, Comini L, Curello S, Ferrari R, Knight R and Latchman D: Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation 104: 253-256, 2001.
7. Salmon AH and Satchell SC: Endothelial glycocalyx dysfunction in disease: Albuminuria and increased microvascular permeability. J Pathol 226: 562-574, 2012.
8. Liu Y, Lian K, Zhang L, Wang R, Yi F, Gao C, Xin C, Zhu D, Li Y, Yan W, et al: TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol 109: 415, 2014.
9. Xu CE, Zhang MY, Zou CW and Guo L: Evaluation of the pharmacological function of ulinastatin in experimental animals. Molecules 17: 9070-9080, 2012.
10. Wang N, Liu X, Zheng X, Cao H, Wei G, Zhu Y, Fan S, Zhou H and Zheng J: Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol 17: 799-807, 2013.
11. Cao YZ, Tu YY, Chen X, Wang BL, Zhong YX and Liu MH: Protective effect of Ulinastatin against murine models of sepsis: Inhibition of TNF-α and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol 64: 543-547, 2012.
12. Huang N, Wang F, Wang Y, Hou J, Li J and Deng X: Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res 182: 296-302, 2013.
13. Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND and Iyer S: Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: A multicenter randomized controlled study. Intensive Care Med 40: 830-838, 2014.
14. Bashir F, Rather MA, Saleem B and Hamid A: a prospective, randomized study using ulinastatin for the treatment of patients with severe sepsis. JEMDS 3: 12241-12246, 2014.
15. Shi X, Sun M, Liu H, Yao Y and Song Y: Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett 339: 159-166, 2013.
16. Johnson R: Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol Dis 46: 245-254, 2012.
17. Congrains A, Kamide K, Oguro R, Yasuda O, Miyata K, Yamamoto E, Kawai T, Kusunoki H, Yamamoto H, Takeya Y, et al: Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis 220: 449-455, 2012.
18. Spizzo R, Almeida MI, Colombatti A, Calin GA and Martin L: Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene 31: 4577-4587, 2012.
19. Guo F, Li Y, Liu Y, Wang J, Li Y and Li G: Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin (Shanghai) 42: 224-229, 2010.
20. Brooks HF, Moss RF, Davies NA, Jalan R and Davies DC: Caecal ligation and puncture induced sepsis in the rat results in increased brain water content and perimicrovessel oedema. Metab Brain Dis 29: 837-843, 2014.
21. Xia JB, Liu GH, Chen ZY, Mao CZ, Zhou DC, Wu HY, Park KS, Zhao H, Kim SK, Cai DQ, et al: Hypoxia/ischemia promotes CXCL10 expression in cardiac microvascular endothelial cells by NFκB activation. Cytokine 81: 63-70, 2016.
22. Wang FY, Fang B, Qiang XH, Yu TO, Zhong JR, Cao J and Zhou LX: The efficacy and immunomodulatory effects of ulinastatin and thymosin α1 for sepsis: A systematic review and meta-analysis. Biomed Res Int 2016: 9508493, 2016.
23. Tsoyi K, Lee TY, Lee YS, Kim HJ, Seo HG, Lee JH and Chang KC: Heme-oxygenase-1 induction and carbon monoxide-releasing molecule inhibit lipopolysaccharide (LPS)-induced high-mobility group box 1 release in vitro and improve survival of mice in LPS-and cecal ligation and puncture-induced sepsis model in vivo. Mol Pharmacol 76: 173-182, 2009.
24. Djoumerska-Alexieva I, Pashova S, Vassilev T and Pashov A: The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response. Autoimmun Rev 12: 653-656, 2013.
25. Lee WL and Slutsky AS: Sepsis and endothelial permeability. N Engl J Med 363: 689-691, 2010.
26. Janicek A, Tharakan B, Sawant DA, Hunter FA and Childs EW: Lipopolysaccharide-induced endothelial cell hyperpermeability: Role of mitochondrial apoptotic signaling pathway. J Surg Res 172: 330, 2012.
27. Hu CL, Xia JM, Cai J, Li X, Liao XX, Li H, Zhan H, Dai G and Jing XL: Ulinastatin attenuates oxidation, inflammation and neural apoptosis in the cerebral cortex of adult rats with ventricular fibrillation after cardiopulmonary resuscitation. Clinics (Sao Paulo) 68: 1231-1238, 2013.
28. Miura M, Sugiura T, Aimi Y, Yasuda K, Ito S, Baba E and Katsuya H: Effects of ulinastatin on PMNL and vascular endothelial injury in patients undergoing open heart surgery with CPB. Masui 47: 29-35, 1998 (In Japanese).
29. Li G, Li T, Li Y, Cai S, Zhang Z, Zeng Z, Wang X, Gao Y, Li Y and Chen Z: Ulinastatin inhibits oxidant-induced endothelial hyperpermeability and apoptotic signaling. Int J Clin Exp Pathol 7: 7342-7350, 2014.
30. Lin B, Liu Y, Li T, Zeng K, Cai S, Zeng Z, Lin C, Chen Z and Gao Y: Ulinastatin mediates protection against vascular hyperpermeability following hemorrhagic shock. Int J Clin Exp Pathol 8: 7685-7693, 2015.
31. Atlante A, Calissano P, Bobba A, Azzariti A, Marra E and Passarella S: Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. J Biol Chem 275: 37159-37166, 2000.
32. Sinha K, Das J, Pal PB and Sil PC: Oxidative stress: The mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol 87: 1157-1180, 2013.
33. Childs EW, Tharakan B, Hunter FA, Tinsley JH and Cao X: Apoptotic signaling induces hyperpermeability following hemorrhagic shock. Am J Physiol Heart Circ Physiol 292: H3179-H3189, 2007.
34. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22: 8031-8041, 2003.
35. Ying L, Chen Q, Wang Y, Zhou Z, Huang Y and Qiu F: Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 8: 2289-2294, 2012.
36. Xu C, Yang M, Tian J, Wang X and Li Z: MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol 39: 169-175, 2011.
37. Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, Wei M, Shen J, Hou J, Gao X, et al: Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol 190: 2278-2287, 2013.
38. Gutschner T, Hämmerle M and Diederichs S: MALAT1-A paradigm for long noncoding RNA function in cancer. J Mol Med (Berl) 91: 791-801, 2013.
39. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and Akslen LA: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273, 2006.
40. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274-7284, 2008.
41. Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, Zhang J and Huang H: LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget 6: 41045-41055, 2015.
42. Xie L, Zhang Z, Tan Z, He R, Zeng X, Xie Y, Li S, Tang G, Tang H and He X: MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Mol Cell Biochem 392: 153-159, 2014.
43. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, Guo Z and Wang L: Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep 32: 2485-2492, 2014.